title: Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
authors.affiliation: Zabi Wardak and Hak Choy, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Zabi
authors.initials: Z
authors.lastname: Wardak
authors.affiliation: Zabi Wardak and Hak Choy, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Hak
authors.initials: H
authors.lastname: Choy
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000201:enzymology / Q000556:secondary / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology / Q000556:secondary / Q000628:therapy*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D057915:Drug Substitution; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D016634:Radiosurgery / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases